UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2018-08, Vol.12 (suppl_2), p.S653-S668

2018

Volltextzugriff (PDF)

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Journal of Crohn's and colitis, 2019-01, Vol.13 (1), p.50-57

2019

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis

Journal of clinical pharmacology, 2018-03, Vol.58 (3), p.386-398

2018

Volltextzugriff (PDF)

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging

The American journal of gastroenterology, 2013-12, Vol.108 (12), p.1891-1900

2013

Volltextzugriff (PDF)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Inflammatory bowel diseases, 2019-05, Vol.25 (6), p.1028-1035

2019

Volltextzugriff (PDF)

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2016-02, Vol.150 (2), p.477-487.e9

2016

Volltextzugriff (PDF)

Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2016-02, Vol.150 (2), p.389-395.e3

2016

Volltextzugriff (PDF)

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis

Journal of Crohn's and colitis, 2017-05, Vol.11 (5), p.jjw189-620

2017

Volltextzugriff (PDF)

Discovery of Biomarkers of Response in Early Drug Development

Journal of Crohn's and colitis, 2016-09, Vol.10 (suppl_2), p.S560-S566

2016

Volltextzugriff (PDF)

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Gut, 2013-08, Vol.62 (8), p.1122-1130

2013

Volltextzugriff (PDF)

Su1921 - Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn’s Disease: A Gemini 2 Post hoc Analysis

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S597-S597

2017

Volltextzugriff (PDF)

Inhibition of platelet aggregation with glyceryl trinitrate and xanthine oxidoreductase

The Journal of pharmacology and experimental therapeutics, 2000-01, Vol.292 (1), p.326

2000

Volltextzugriff (PDF)

Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn’s Disease: A Gemini 2 Post hoc Analysis

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S597-S597

2017

Volltextzugriff (PDF)

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis

Journal of Crohn's and colitis, 2017-05, Vol.11 (5), p.610-620

2017

Volltextzugriff (PDF)

Su1240 Comparison of Rectosigmoidoscopy and Colonoscopy for Assessment of Endoscopic Activity in Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-449-S-449

2015

Volltextzugriff (PDF)

Su1934 - Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S602-S602

2017

Volltextzugriff (PDF)

Su1931 - Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S601-S601

2017

Volltextzugriff (PDF)

Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S602-S602

2017

Volltextzugriff (PDF)

Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S601-S601

2017

Volltextzugriff (PDF)

Sa1145 AlphaE (αE) Integrin Protein and Gene Expression Are Augmented in the Ileum Relative to the Colon in Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-239-S-239

2015

Volltextzugriff (PDF)

ACE inhibition : Postsynaptic adrenergic sympatholytic action in men

Circulation (New York, N.Y.), 1997-08, Vol.96 (3), p.911-915

1997

Volltextzugriff (PDF)

Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-442-S-442

2015

Volltextzugriff (PDF)

Su1221 Symptom Scores Do Not Accurately Reflect Level of Mucosal Inflammation in Patients With Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-442-S-442

2015

Volltextzugriff (PDF)

995 Feasibility, Precision and Reproducibility of MR Enterography for Detection of Inflammation in Crohn's Disease in a Multicenter Clinical Trial

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-174-S-174

2014

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)

Erscheinungsjahr

n.n

Thema

Humans
(28)
Science & Technology
(28)
Life Sciences & Biomedicine
(24)
Gastroenterology And Hepatology
(19)
Adult
(14)
Female
(13)
Male
(12)
Inflammatory Bowel Disease
(9)
Middle Aged
(9)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(8)
Biological And Medical Sciences
(8)
Gastroenterology & Hepatology
(8)
Medical Sciences
(8)
Colitis, Ulcerative - Drug Therapy
(7)
Aged
(6)
Double-Blind Method
(6)
Gastrointestinal Agents - Therapeutic Use
(6)
Adolescent
(5)
Animals
(5)
Covid-19
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis

Discovery of Biomarkers of Response in Early Drug Development

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Su1921 - Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn’s Disease: A Gemini 2 Post hoc Analysis

Inhibition of platelet aggregation with glyceryl trinitrate and xanthine oxidoreductase

Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn’s Disease: A Gemini 2 Post hoc Analysis

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis

Su1240 Comparison of Rectosigmoidoscopy and Colonoscopy for Assessment of Endoscopic Activity in Ulcerative Colitis

Su1934 - Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study

Su1931 - Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study

Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study

Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study

Sa1145 AlphaE (αE) Integrin Protein and Gene Expression Are Augmented in the Ileum Relative to the Colon in Crohn's Disease

ACE inhibition : Postsynaptic adrenergic sympatholytic action in men

Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis

Su1221 Symptom Scores Do Not Accurately Reflect Level of Mucosal Inflammation in Patients With Crohn's Disease

995 Feasibility, Precision and Reproducibility of MR Enterography for Detection of Inflammation in Crohn's Disease in a Multicenter Clinical Trial

Suchergebnisse filtern